New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Scribe Therapeutics Inc.

SCTX

Healthcare Biotechnology

Scribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.

12.07 1.15 −8.70%

After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.

Market cap
$250.4M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Payout ratio
—
Dec '25
P/E ratio
0.00
P/S ratio
1.84
P/FCF ratio
0.00
P/Operating CF
(4.75)
P/B ratio
0.00
Price to Tangible BV
0.00
EV/Sales
0.36
EV/EBITDA
0.00
EV/Operating CF
0.00
EV/FCF
0.00
Earnings Yield
(60.70%)
Free Cash Flow Yield
0.00%
Revenue per Share
21.07
EV/EBIT
0.00
Price to Operating Income
0.00
Other line items
Graham Net Nets
(1.07)
Graham Number
0.00

Fold the line items

Columns are period end dates · fundamentals updated Nov 18, 2026